NeoRecormon

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
15-03-2023
Tabia za bidhaa Tabia za bidhaa (SPC)
15-03-2023

Viambatanisho vya kazi:

epoetin beta

Inapatikana kutoka:

Roche Registration GmbH

ATC kanuni:

B03XA01

INN (Jina la Kimataifa):

epoetin beta

Kundi la matibabu:

Antianemic preparations

Eneo la matibabu:

Kidney Failure, Chronic; Anemia; Cancer; Blood Transfusion, Autologous

Matibabu dalili:

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients;treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy;increasing the yield of autologous blood from patients in a pre-donation programme. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10 - 13 g/dl [6.21 - 8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).

Bidhaa muhtasari:

Revision: 33

Idhini hali ya:

Authorised

Idhini ya tarehe:

1997-07-16

Taarifa za kipeperushi

                                48
B. PACKAGE LEAFLET
49
PACKAGE LEAFLET: INFORMATION FOR THE USER
NEORECORMON 500 IU
NEORECORMON 2000 IU
NEORECORMON 3000 IU
NEORECORMON 4000 IU
NEORECORMON 5000 IU
NEORECORMON 6000 IU
NEORECORMON 10,000 IU
NEORECORMON 20,000 IU
NEORECORMON 30,000 IU
SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
epoetin beta
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs or illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What NeoRecormon is and what it is used for
2.
What you need to know before you use NeoRecormon
3.
How to use NeoRecormon
4.
Possible side effects
5.
How to store NeoRecormon
6.
Content of the pack and other information
1.
WHAT NEORECORMON IS AND WHAT IT IS USED FOR
NeoRecormon is a clear, colourless solution for injection under the
skin
_(subcutaneously)_
or into a
vein
_(intravenously). _
It contains a hormone called
_epoetin beta_
, which stimulates the production of red
blood cells. Epoetin beta is produced by a specialised genetic
technology and works in exactly the
same way as the natural hormone erythropoietin.
You must talk to your doctor if you do not feel better or if you feel
worse.
NeoRecormon is indicated for:
•
TREATING SYMPTOMATIC ANAEMIA CAUSED BY CHRONIC KIDNEY DISEASE
(renal anaemia) in patients
on dialysis, or not yet on dialysis.
•
PREVENTING ANAEMIA IN PREMATURE INFANTS
(weighing 750 to 1500 g and born at less than
34 weeks).
•
TREATING ANAEMIA WITH RELATED SYMPTOMS IN ADULT CANCER PATIENTS
RECEIVING CHEMOTHERAPY
•
TREATING PEOPLE DONATING THEIR OWN BLOOD BEFORE SURGERY.
The injections of epoetin beta will
increas
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
NeoRecormon 500 IU solution for injection in pre-filled syringe
NeoRecormon 2000 IU solution for injection in pre-filled syringe
NeoRecormon 3000 IU solution for injection in pre-filled syringe
NeoRecormon 4000 IU solution for injection in pre-filled syringe
NeoRecormon 5000 IU solution for injection in pre-filled syringe
NeoRecormon 6000 IU solution for injection in pre-filled syringe
NeoRecormon 10,000 IU solution for injection in pre-filled syringe
NeoRecormon 20,000 IU solution for injection in pre-filled syringe
NeoRecormon 30,000 IU solution for injection in pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
NeoRecormon 500 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains 500
international units (IU)
corresponding to 4.15 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 1667 IU epoetin beta.
NeoRecormon 2000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains
2000 international units (IU)
corresponding to 16.6 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 6667 IU epoetin beta.
NeoRecormon 3000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains
3000 international units (IU)
corresponding to 24.9 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 10,000 IU epoetin beta.
NeoRecormon 4000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains
4000 international units (IU)
corresponding to 33.2 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 13,333 IU epoetin beta.
NeoRecormon 5000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kibulgaria 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kihispania 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kicheki 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kidenmaki 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kijerumani 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kiestonia 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kigiriki 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kifaransa 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kiitaliano 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kilatvia 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kilithuania 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kihungari 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kimalta 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kiholanzi 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kipolandi 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kireno 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kiromania 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kislovakia 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kislovenia 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kifinlandi 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kiswidi 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 03-12-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kinorwe 15-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 15-03-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 15-03-2023
Tabia za bidhaa Tabia za bidhaa Kroeshia 15-03-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 03-12-2015

Tafuta arifu zinazohusiana na bidhaa hii

Tazama historia ya hati